201920182017201620152014 December 14, 2017 Summary ToggleSpero Therapeutics Announces 3Q17 Operating Results and Pipeline Update November 13, 2017 Summary ToggleSpero Therapeutics Announces Underwriters’ Option Exercise November 06, 2017 Summary ToggleSpero Therapeutics Announces Closing of Initial Public Offering November 01, 2017 Summary ToggleSpero Therapeutics Announces Pricing of Initial Public Offering October 23, 2017 Summary ToggleSpero Therapeutics Launches Initial Public Offering October 20, 2017 Summary ToggleSpero Therapeutics Initiates Clinical Program For Oral Carbapenem SPR994 October 10, 2017 Summary ToggleSpero Therapeutics Licenses Exclusive Rights to SPR994, a Novel Oral Carbapenem Being Studied for Use in Adults October 06, 2017 Summary ToggleSpero Therapeutics Files Registration Statement for Proposed Initial Public Offering October 03, 2017 Summary ToggleSpero Therapeutics Announces Positive Phase 1 Clinical Data From Potentiator Platform September 06, 2017 Summary ToggleSpero Announces Appointment of Frank Thomas to its Board of Directors and Promotions within Leadership Team Pagination Current page 1 Page 2 Page 3 Next page Next Last page Last
